These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 12015416)

  • 41. Mesenchymal Stem Cells and Cardiomyocytes Interplay to Prevent Myocardial Hypertrophy.
    Cai B; Tan X; Zhang Y; Li X; Wang X; Zhu J; Wang Y; Yang F; Wang B; Liu Y; Xu C; Pan Z; Wang N; Yang B; Lu Y
    Stem Cells Transl Med; 2015 Dec; 4(12):1425-35. PubMed ID: 26586774
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dual specific phosphatase 12 ameliorates cardiac hypertrophy in response to pressure overload.
    Li WM; Zhao YF; Zhu GF; Peng WH; Zhu MY; Yu XJ; Chen W; Xu DC; Xu YW
    Clin Sci (Lond); 2017 Jan; 131(2):141-154. PubMed ID: 27702885
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Role of calcineurin in angiotensin II-induced cardiac myocyte hypertrophy of rats.
    Fu M; Zhang J; Xu S; Pang Y; Liu N; Tang C
    Chin Med Sci J; 2001 Mar; 16(1):1-4. PubMed ID: 12899339
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Reversal of cardiac hypertrophy in transgenic disease models by calcineurin inhibition.
    Lim HW; De Windt LJ; Mante J; Kimball TR; Witt SA; Sussman MA; Molkentin JD
    J Mol Cell Cardiol; 2000 Apr; 32(4):697-709. PubMed ID: 10756124
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ca²⁺ signal-induced cardiomyocyte hypertrophy through activation of myocardin.
    Li M; Wang N; Gong HQ; Li WZ; Liao XH; Yang XL; He HP; Cao DS; Zhang TC
    Gene; 2015 Feb; 557(1):43-51. PubMed ID: 25485719
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Hypertrophy of the heart: calcineurin-NFAT pathway may be a new therapeutic target].
    Zhang YJ; Dong LF; Wang YL
    Yao Xue Xue Bao; 2006 Oct; 41(10):913-6. PubMed ID: 17184105
    [No Abstract]   [Full Text] [Related]  

  • 47. Signalling pathways in cardiac myocyte hypertrophy.
    Sugden PH
    Ann Med; 2001 Dec; 33(9):611-22. PubMed ID: 11817656
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mitochondrial adaptations to physiological vs. pathological cardiac hypertrophy.
    Abel ED; Doenst T
    Cardiovasc Res; 2011 May; 90(2):234-42. PubMed ID: 21257612
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The alteration of protein prenylation induces cardiomyocyte hypertrophy through Rheb-mTORC1 signalling and leads to chronic heart failure.
    Xu N; Guan S; Chen Z; Yu Y; Xie J; Pan FY; Zhao NW; Liu L; Yang ZZ; Gao X; Xu B; Li CJ
    J Pathol; 2015 Apr; 235(5):672-85. PubMed ID: 25385233
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Differences between pathological and physiological cardiac hypertrophy: novel therapeutic strategies to treat heart failure.
    McMullen JR; Jennings GL
    Clin Exp Pharmacol Physiol; 2007 Apr; 34(4):255-62. PubMed ID: 17324134
    [TBL] [Abstract][Full Text] [Related]  

  • 51. IGF-1 induces skeletal myocyte hypertrophy through calcineurin in association with GATA-2 and NF-ATc1.
    Musarò A; McCullagh KJ; Naya FJ; Olson EN; Rosenthal N
    Nature; 1999 Aug; 400(6744):581-5. PubMed ID: 10448862
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Decreased KCNE2 Expression Participates in the Development of Cardiac Hypertrophy by Regulation of Calcineurin-NFAT (Nuclear Factor of Activated T Cells) and Mitogen-Activated Protein Kinase Pathways.
    Liu W; Deng J; Ding W; Wang G; Shen Y; Zheng J; Zhang X; Luo Y; Lv C; Wang Y; Chen L; Yan D; Boudreau RL; Song LS; Liu J
    Circ Heart Fail; 2017 Jun; 10(6):. PubMed ID: 28611128
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Activation of the calcineurin/NFAT signalling cascade starts early in human hypertrophic myocardium.
    Diedrichs H; Hagemeister J; Chi M; Boelck B; Müller-Ehmsen J; Schneider CA
    J Int Med Res; 2007; 35(6):803-18. PubMed ID: 18034994
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Calcineurin-AKAP interactions: therapeutic targeting of a pleiotropic enzyme with a little help from its friends.
    Gildart M; Kapiloff MS; Dodge-Kafka KL
    J Physiol; 2020 Jul; 598(14):3029-3042. PubMed ID: 30488951
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A Review of Calcineurin Biophysics with Implications for Cardiac Physiology.
    Williams RB; Johnson CN
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768996
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Molecular pathways underlying cardiac remodeling during pathophysiological stimulation.
    Kehat I; Molkentin JD
    Circulation; 2010 Dec; 122(25):2727-35. PubMed ID: 21173361
    [No Abstract]   [Full Text] [Related]  

  • 57. Calcineurin--the missing link in cardiac hypertrophy.
    Izumo S; Aoki H
    Nat Med; 1998 Jun; 4(6):661-2. PubMed ID: 9623967
    [No Abstract]   [Full Text] [Related]  

  • 58. Prevention of cardiac hypertrophy by calcineurin inhibition: hope or hype?
    Olson EN; Molkentin JD
    Circ Res; 1999 Apr; 84(6):623-32. PubMed ID: 10189350
    [No Abstract]   [Full Text] [Related]  

  • 59. Signaling pathways mediating the response to hypertrophic stress in the heart.
    Force T; Hajjar R; Del Monte F; Rosenzweig A; Choukroun G
    Gene Expr; 1999; 7(4-6):337-48. PubMed ID: 10440234
    [TBL] [Abstract][Full Text] [Related]  

  • 60. When one says yes and the other says no; does calcineurin participate in physiologic cardiac hypertrophy?
    Ritchie JA; Ng JQ; Kemi OJ
    Adv Physiol Educ; 2022 Mar; 46(1):84-95. PubMed ID: 34762541
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.